Login to Your Account



PART OF PHASE I EXPERIENCE

Oncomed halts phase I trials of Bayer-partnered cancer drugs

By Michael Fitzhugh
Staff Writer

Friday, June 13, 2014
Oncomed Pharmaceuticals Inc.'s shares dipped as much as 24 percent briefly after the company halted six phase Ib trials testing two Bayer AG-partnered monoclonal antibodies targeting the Wnt pathway in cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription